Aquestive announces FDA review of Anaphylm sublingual film
- Aquestive Therapeutics (AQST) on Thursday announced that the U.S. FDA accepted its resubmitted marketing application for Anaphylm sublingual film, an epinephrine formulation designed for the emergency treatment of severe allergic reactions.
- The company's resubmitted New Drug Application specifically seeks the
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.